News | 18 September 2012
There has been concern within the investment community about the long term effects of new legislation allowing for new generic biotech drugs (biosimilars). Last February, the U.S. Food and Drug Administration (FDA) published biosimilar guidelines as a ...
Click on the link to read the full article at Seeking Alpha
(This link will open in a new window)